{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:59:53Z","timestamp":1789901993115,"version":"4.0.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/rlu.0000000000000973","type":"journal-article","created":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T12:25:12Z","timestamp":1441974312000},"page":"204-206","source":"Crossref","is-referenced-by-count":12,"title":["Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation"],"prefix":"10.1097","volume":"41","author":[{"given":"William","family":"Makis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karey","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.B.","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210204","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1210\/jc.2009-2830","article-title":"A current review of the etiology, diagnosis and treatment of pediatric pheochromocytoma and paraganglioma.","volume":"95","author":"Waguespack","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-6-20210204","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2011.34.6353","article-title":"Metastatic pheochromocytomaparaganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.","volume":"29","author":"King","year":"2011","journal-title":"J Clin Oncol"},{"key":"R3-6-20210204","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ctrv.2010.07.002","article-title":"Malignant pheochromocytomas and paragangliomasthe importance of a multidisciplinary approach.","volume":"37","author":"Andersen","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R4-6-20210204","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis.","volume":"80","author":"Van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R5-6-20210204","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose 131Imetaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"key":"R6-6-20210204","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-6-20210204","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/MPA.0b013e31825c53fa","article-title":"Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma).","volume":"42","author":"Bourcier","year":"2013","journal-title":"Pancreas"},{"key":"R8-6-20210204","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s11255-014-0663-8","article-title":"Sunitinib for refractory malignant pheochromocytoma: two case reports.","volume":"46","author":"Hata","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"R9-6-20210204","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1210\/jc.2008-1836","article-title":"Rationale and evidence for sunitinib in the treatment of malignant paragangliomapheochromocytoma.","volume":"94","author":"Joshua","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 1","key":"R10-6-20210204","first-page":"57","article-title":"Synergistic effect of combined treatment with 177Lu-DOTATATE and everolimus in neuroendocrine tumors as monitored by 18F-FDG PET: studies in human neuroendocrine xenografts.","volume":"53","author":"Johnbeck","year":"2012","journal-title":"J Nucl Med"},{"key":"R11-6-20210204","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-14-0488","article-title":"Radionuclide therapy in neuroendocrine tumors.","volume":"172","author":"Van der Zwan","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"R12-6-20210204","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13550-014-0021-y","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA0Tyr3octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model.","volume":"4","author":"Bison","year":"2014","journal-title":"EJNMMI Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000000973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:13:18Z","timestamp":1620972798000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201603000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000000973","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}